Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme: Clinical article

Journal of Neurosurgery

Volumn 118, Issue 4, 2013, Pages 859-865

  Guthrie, Greg D ^a   Eljamel, Sam ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Anticonvulsant; Antiepileptic drug; Glioblastoma multiforme; Oncology; Sodium valproate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; COHORT ANALYSIS; DRUG EFFECT; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; LOG RANK TEST; META ANALYSIS; PRIORITY JOURNAL; SEIZURE; SURVIVAL; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; BRAIN NEOPLASMS; CARBAMAZEPINE; COHORT STUDIES; FEMALE; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENYTOIN; SURVIVAL RATE; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84875862383     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.10.JNS12169     Document Type: Article

References (18)

1. Beutler AS, Li S, Nicol R, Walsh MJ: Carbamazepine is an inhibitor of histone deacetylases. Life Sci 76:3107-3115, 2005
2. Central Brain Tumor Registry of the United States: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008. Hinsdale, IL: CBTRUS, 2011 (http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS-Report- 2004-2008-3-23-2012.pdf) [Accessed October 19, 2012]
3. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, et al: Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24:3651-3656, 2006
4. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M: The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45:737-744, 2004
5. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38, 2008
6. Jaeckle KA, Ballman K, Furth A, Buckner JC: Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207-1213, 2009
7. Marks PA, Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:600-608, 2009
8. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, et al: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54:31-38, 2001
9. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, et al: Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28:2437-2442, 2008
10. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W: P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255-260, 2005
11. Ozbek N, Cakir S, Gursel B, Meydan D: Prognostic significance of seizure in patients with glioblastoma multiforme Neurol India 52:76-78, 2004
12. Perucca E: Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695-714, 2002
13. Riva M, Salmaggi A, Marchioni E, Silvani A, Tomei G, Lorusso L, et al: Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. Neurol Sci 27:345-351, 2006
14. Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 64:2090-2103, 2007
15. Salmaggi A, Silvani A, Merli R, Caroli M, Tomei G, Russo A, et al: Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience. Neurol Sci 29:77-83, 2008
16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
17. Valenzuela-Fernández A, Cabrero JR, Serrador JM, Sánchez-Madrid F: HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18:291-297, 2008
18. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980